Linezolid Resistance in Staphylococcus haemolyticus - Case Series and Review of Literature.
Adult
Aged
Drug Resistance, Bacterial
/ drug effects
Equipment and Supplies
/ microbiology
Female
Glycopeptides
/ pharmacology
Humans
Linezolid
/ pharmacology
Male
Methicillin Resistance
/ drug effects
Microbial Sensitivity Tests
Middle Aged
Staphylococcal Infections
/ drug therapy
Staphylococcus haemolyticus
/ drug effects
Treatment Outcome
Young Adult
Coagulase negative Staphylococci
Staphylococcus haemolyticus
antibiotics
drug resistance
linezolid
vancomycin-resistant enterococci
Journal
Infectious disorders drug targets
ISSN: 2212-3989
Titre abrégé: Infect Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269158
Informations de publication
Date de publication:
2020
2020
Historique:
received:
24
04
2019
revised:
25
05
2019
accepted:
27
05
2019
pubmed:
8
8
2019
medline:
29
5
2021
entrez:
8
8
2019
Statut:
ppublish
Résumé
Coagulase negative Staphylococci (CoNS) are important. The common antibiotics used for the treatment of the infections caused by CoNS are penicillin, oxacillin, ciprofloxacin, clindamycin, erythromycin, gentamicin, and vancomycin. Linezolid is an oxazolidinone group of antibiotic with activity against Gram-positive bacteria. It is used for the treatment of serious infections caused by Gram-positive bacteria resistant to other antibiotics, including streptococci, vancomycin-resistant enterococci (VRE). This study emphasizes on the judicious use of newer antibiotics to contain the spread of resistance. We are discussing five cases of Linezolid resistant Staphylococcus Haemolyticus which were reported in our laboratory during one year from patients with device related infections and also review of literature is being presented for an update. In our study, the isolates were resistant to other groups of antimicrobials but susceptible to glycopeptides. All the isolates were methicillin-resistant. Linezolid is approved as an alternative drug to be given for catheter-related bloodstream infections. In earlier studies, linezolid-resistant staphylococci have been reported increasingly all over the world. This study is to create awareness amongst clinicians that improper and excessive use of linezolid will make this antibiotic-resistant and thus will be of no help in future, so judicious and relevant use of antibiotics needs to be emphasized.
Sections du résumé
BACKGROUND
BACKGROUND
Coagulase negative Staphylococci (CoNS) are important. The common antibiotics used for the treatment of the infections caused by CoNS are penicillin, oxacillin, ciprofloxacin, clindamycin, erythromycin, gentamicin, and vancomycin. Linezolid is an oxazolidinone group of antibiotic with activity against Gram-positive bacteria. It is used for the treatment of serious infections caused by Gram-positive bacteria resistant to other antibiotics, including streptococci, vancomycin-resistant enterococci (VRE).
AIMS AND OBJECTIVE
OBJECTIVE
This study emphasizes on the judicious use of newer antibiotics to contain the spread of resistance.
METHOD
METHODS
We are discussing five cases of Linezolid resistant Staphylococcus Haemolyticus which were reported in our laboratory during one year from patients with device related infections and also review of literature is being presented for an update.
RESULT
RESULTS
In our study, the isolates were resistant to other groups of antimicrobials but susceptible to glycopeptides. All the isolates were methicillin-resistant.
CONCLUSION
CONCLUSIONS
Linezolid is approved as an alternative drug to be given for catheter-related bloodstream infections. In earlier studies, linezolid-resistant staphylococci have been reported increasingly all over the world. This study is to create awareness amongst clinicians that improper and excessive use of linezolid will make this antibiotic-resistant and thus will be of no help in future, so judicious and relevant use of antibiotics needs to be emphasized.
Identifiants
pubmed: 31389316
pii: IDDT-EPUB-100184
doi: 10.2174/1871526519666190807152850
doi:
Substances chimiques
Glycopeptides
0
Linezolid
ISQ9I6J12J
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
713-717Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.